Skip to main content

Table 4 Pathologic results after neoadjuvant chemotherapy and response to chemotherapy

From: Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study

Characteristic

ER-Positive

ER-Negative

Age<35

35≤Age<50

P-value

Age<35

35≤Age<50

P-value

(N = 147)

(N = 901)

(N = 134)

(N = 663)

Postoperative T stage

 ypT0, ypTis

6 (4.1)

27 (3.0)

0.638

28 (20.9)

111 (16.8)

0.310

 ypT1-ypT4

141 (95.9)

874 (97.0)

 

106 (79.1)

552 (83.2)

 

 ypT1

47 (32.2)

351 (39.1)

 

29 (21.6)

188 (28.4)

 

 ypT2

69 (47.3)

348 (38.8)

 

45 (33.6)

204 (30.8)

 

 ypT3

22 (15.1)

158 (17.6)

 

23 (17.2)

94 (14.2)

 

 ypT4

2 (1.4)

14 (1.3)

 

0 (0)

0 (0)

 

Postoperative N stage

 ypN0

55 (37.4)

296 (32.9)

0.515

77 (57.5)

301 (45.4)

0.016

 pN1-ypN3

92 (62.6)

604 (67.0)

 

52 (38.8)

323 (47.9)

 

Pathologic response

 Complete: breast and axilla

7 (4.8)

37 (4.1)

0.713

26 (19.4)

74 (11.2)

0.009

 Complete: breast-only

1 (0.7)

3 (0.3)

1.000

3 (2.2)

45 (6.7)

0.006

  1. NOTE: Data are presented as No. (%) unless otherwise specified
  2. ER estrogen receptor